Keytruda

Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Fierce Pharma
Merck
Pfizer
immuno-oncology
M&A
Keytruda
Prevnar
Ibrance
Xeljanz
Xtandi
Flag link:
Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment
Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment
Marketwatch
Incyte
Merck
melanoma
epacadostat
Keytruda
clinical trials
metastatic melanoma
Flag link:
Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer (TSRO)
Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer (TSRO)
CP Wire
Tesaro
Zejula
Merck
Keytruda
platinum-resistant ovarian cancer
niraparib
clinical trials vaccines
Flag link:
Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer
Tesaro
Zejula
Merck
Keytruda
platinum-resistant ovarian cancer
niraparib
clinical trials
Flag link:
Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?
Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?
Fierce Pharma
Roche
Tecentriq
squamous non-small cell lung cancer
Merck
Keytruda
Flag link:
Merck's Keytruda shows up its rivals with NICE backing in bladder cancer
Merck's Keytruda shows up its rivals with NICE backing in bladder cancer
Fierce Pharma
Merck
Keytruda
NICE
bladder cancer
Flag link:
Incyte study could bring lessons for cancer immunotherapy
Incyte study could bring lessons for cancer immunotherapy
Biopharma Dive
Incyte
cancer immunotherapy
metastatic melanoma
Merck
Keytruda
Flag link:
[video]How Convenience Can Give Drugmakers a Competitive Edge
[video]How Convenience Can Give Drugmakers a Competitive Edge
Motley Fool
convenience
Merck
Bristol-Myers Squibb
dosing
Opdivo
Keytruda
Flag link:
Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star
Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star
Endpoints
Merck
Keytruda
Eisai
Lenvima
Flag link:
Merck says Keytruda's explosive growth prompts need for new Ireland plant with 350 jobs
Merck says Keytruda's explosive growth prompts need for new Ireland plant with 350 jobs
Fierce Pharma
Merck
Keytruda
Ireland
hirings
drug manufacturing
Flag link:
Merck quarterly profit beats on Keytruda demand
Merck quarterly profit beats on Keytruda demand
Yahoo/Reuters
Merck
earnings
Keytruda
Flag link:
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
Motley Fool
Merck
Keytruda
AbbVie
Humira
Mavyret
Bristol-Myers Squibb
Eliquis
Pfizer
Ibrance
Flag link:
Merck & Co.’s shares rise over 7% thanks to new positive clinical results from Keytruda
Merck & Co.’s shares rise over 7% thanks to new positive clinical results from Keytruda
GoinPharma
Merck
Keytruda
non-squamous cell non-small cell lung cancer
Flag link:
Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector
Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector
GoinPharma
Eisai
Merck
Bristol-Myers Squibb
kidney cancer
Keytruda
Lenvima
Opdivo
Flag link:
Merck's Keytruda extends lung cancer survival in combination trial
Merck's Keytruda extends lung cancer survival in combination trial
Yahoo/Reuters
Merck
Keytruda
lung cancer
clinical trials
Flag link:
Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return
Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return
Fierce Pharma
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
melanoma
Flag link:
Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field
Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
kidney cancer
Flag link:
Cancer Space Update: New Regulatory Status for 3 Major Drugs
Cancer Space Update: New Regulatory Status for 3 Major Drugs
Yahoo/Zacks.com
cancer
Merck
Japan
Keytruda
Seattle Genetics
Adcetris
Novartis
Kisqali
Flag link:
One of Merck’s pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK
One of Merck’s pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK
Endpoints
Merck
Keytruda
stomach cancer
clinical trials
Flag link:
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Motley Fool
Merck
Keytruda
earnings
Flag link:

Pages